CD38 and Miyoshi myopathy: Bispecific antibodies (BsAbs) have emerged as promising agents with overall response rates (ORR) of 61–74% in patients with relapsed/refractory MM (RRMM) who have previously been treated with proteasome inhibitors, immunomodulatory drugs, and anti-CD38 antibodies [1,2,3,4].